The Mpz promoter has been previously shown to drive selective expression of gene therapies in Schwann cells using either a lentiviral vector or the AAV9 serotype4,31 as well as in studies targeting Schwannomas using the AAV1 serotype33. Here, MPZ is linked to schwannoma.